Nippon Shinyaku Co., Ltd., commonly referred to as Nippon Shinyaku, is a prominent pharmaceutical company headquartered in Japan. Established in 1923, the company has made significant strides in the healthcare sector, focusing on the development and manufacturing of innovative pharmaceuticals and medical devices. With a strong presence in both domestic and international markets, Nippon Shinyaku operates extensively across Asia, Europe, and North America. The company is renowned for its core products, which include prescription medications, particularly in the fields of oncology, urology, and orthopaedics. Nippon Shinyaku's commitment to research and development has positioned it as a leader in the pharmaceutical industry, with notable achievements in drug discovery and a robust pipeline of new therapies. Through its dedication to improving patient outcomes, Nippon Shinyaku continues to enhance its market position as a trusted provider of high-quality healthcare solutions.
How does Nippon Shinyaku Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Nippon Shinyaku Co's score of 36 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Nippon Shinyaku Co., Ltd. reported total greenhouse gas emissions of approximately 4910000 kg CO2e for Scope 1, 5204000 kg CO2e for Scope 2 (market-based), and a significant 217585000 kg CO2e for Scope 3 emissions. The combined total for Scope 1 and 2 emissions was about 6803000 kg CO2e. This reflects a notable increase in emissions compared to previous years, with Scope 1 emissions rising from 4366000 kg CO2e in 2022 and Scope 2 emissions from 4057000 kg CO2e. Nippon Shinyaku has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030, using FY2020 as the baseline. Additionally, the company targets a 25% reduction in Scope 3 emissions from purchased goods and services within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are classified under the 1.5°C pathway, indicating a commitment to significant climate action. Overall, Nippon Shinyaku's emissions data and reduction targets highlight its ongoing efforts to address climate change within the pharmaceutical sector, although the recent increase in emissions underscores the challenges faced in achieving these goals.
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 428,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | 00,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nippon Shinyaku Co is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
